Breyanzi Is Third To Market, But BMS’s First CAR-T Therapy Priced Above Competitors

Third Cell Therapy For Lymphoma Approved In The US

FDA - Food and Drug Administration approved text on document above stethoscope
Breyanzi was approved after an FDA delay related to manufacturing inspections • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip